[1]
|
World Health Organization (2020) World Cancer Report 2020. World Health Organization, Geneva.
https://www.iarc.fr/cards_page/world-cancer-report/
|
[2]
|
Chen, W., Zheng, R., Baade, P.D., Zhang, S., Zeng, H., Bray, F., et al. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132. https://doi.org/10.3322/caac.21338
|
[3]
|
Amin, M.B., Edge, S., Greene, F., et al. (2017) AJCC Cancer Staging Manual. Springer International Publishing, New York, 203-220.
|
[4]
|
Wagner, A.D., Syn, N.L., Moehler, M., Grothe, W., Yong, W.P., Tai, B.C., et al. (2017) Chemotherapy for Advanced Gastric Cancer. Cochrane Database of Systematic Reviews, No. 8, Article No. CD004064.
https://doi.org/10.1002/14651858.CD004064.pub4
|
[5]
|
Leng, C., Li, Y., Qin, J., Ma, J., Liu, X., Cui, Y., et al. (2016) Relationship between Expression of PD-L1 and PD-L2 on Esophageal Squamous Cell Carcinoma and the An-ti-Tumor Effects of CD8+ T Cells. Oncology Reports, 35, 699-708.
https://doi.org/10.3892/or.2015.4435
|
[6]
|
Hughes, P.E., Caenepeel, S. and Wu, L.C. (2016) Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer. Trends in Immunology, 37, 462-476. https://doi.org/10.1016/j.it.2016.04.010
|
[7]
|
Palucka, A.K. and Coussens, L.M. (2016) The Basis of Oncoim-munology. Cell, 164, 1233-1247.
https://doi.org/10.1016/j.cell.2016.01.049
|
[8]
|
Kang, Y.K., Boku, N., Satoh, T., Ryu, M.H., Chao, Y., Kato, K., et al. (2017) Nivolumab in Patients with Advanced Gastric or Gastro-Oesophageal Junction Cancer Refractory to, or Intol-erant of, at Least Two Previous Chemotherapy Regimens (ONO-4538-12,ATTRACTION-2): A Randomised, Dou-ble-Blind, Placebo-Controlled, Phase 3 Trial. Lancet, 390, 2461-2471. https://doi.org/10.1016/S0140-6736(17)31827-5
|
[9]
|
Fuchs, C.S., Doi, T., Jang, R.W., Muro, K., Satoh, T., Ma-chado, M., et al. (2018) Safety and Efficacy of Pembrolizumab Mono Therapy in Patients with Previously Treated Ad-vanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncology, 4, Arti-cle ID: e180013.
|
[10]
|
Wainberg, Z.A., Shitara, K., Van Cutsem, E., Wyrwicz, L., Lee, K.W., Kudaba, I., et al. (2022) Pembrolizumab with or without Chemotherapy versus Chemotherapy alone for Patients with PD-L1 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: Update from the Phase 3 KEYNOTE-062 Trial. Journal of Clin-ical Oncology, 40, 243. https://doi.org/10.1200/JCO.2022.40.4_suppl.243
|
[11]
|
Janjigian, Y.Y., Shitara, K., Moehler, M., Garrido, M., Salman, P., Shen, L., et al. (2021) First-Line Nivolumab plus Chemotherapy versus Chemo-therapy alone for Advanced Gastric, Gastro-Oesophageal Junction, and Oesophageal Adenocarcinoma(CheckMate 649): A Randomised, Open-Label, Phase 3 Trial. Lancet, 398, 27-40.
https://doi.org/10.1016/S0140-6736(21)00797-2
|
[12]
|
Shitara, K., Janjigian, Y.Y., Moehler, M.H., Garrido, M., Gallardo, C., Shen, L., et al. (2022) Nivolumab (NIVO) plus Chemotherapy (Chemo) versus Chemo as First-Line (1L) Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma (GC/GEJC/EAC): Expanded Efficacy, Safety, and Subgroup Analyses from CheckMate 649. Journal of Clinical Oncol-ogy, 40, 240. https://doi.org/10.1200/JCO.2022.40.4_suppl.240
|
[13]
|
Boku, N., Ryu, M.H., Oh, D.Y., Oh, S.C., Chung, H.C., Lee, K.-W., et al. (2020) LBA7_ PR Nivolumab plus Chemotherapy versus Chemotherapy alone in Pa-tients with Previously Untreated Advanced or Recurrent Gastric/Gastroeso- phageal Junction (G/GEJ) Cancer: ATTRACTION-4 (ONO-4538-37) Study. Annals of Oncology, 31, S1192.
https://doi.org/10.1016/j.annonc.2020.08.2297
|
[14]
|
Xu, J., Jiang, H., Pan, Y., Gu, K., Cang, S., Han, L., et al. (2021) LBA53-Sintilimab plus Chemotherapy(Chemo) versus Chemo as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma (ORIENT-16): First Results of a Randomized, Double-Blind, Phase Ⅲ Study. Annals of Oncology, 32, S1331.
https://doi.org/10.1016/j.annonc.2021.08.2133
|
[15]
|
Ji, J., Shen, L., Gao, X., Ji, K., Chen, Y., Xu, N., et al. (2022) A Phase Ib/II, Multicenter, Open-Label Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, Combined with Chemo-therapy (Chemo) as First-Line Therapy for Advanced Gastric (G) or Gastroesophageal Junction (GEJ) Cancer. Journal of Clinical Oncology, 40, 308.
https://doi.org/10.1200/JCO.2022.40.4_suppl.308
|
[16]
|
潘云枫. HER2阳性胃癌免疫治疗的研究进展[J]. 中国肿瘤生物治疗杂志, 2021, 28(1): 90-96
|
[17]
|
程浩, 依荷芭丽•迟, 周全, 应建明, 石素胜. CAR-T在胃癌免疫治疗中的研究进展[J/OL]. 中国肿瘤临床.
https://kns.cnki.net/kcms/detail/12.1099.R.20220129.1559.006.html, 2022-01-30.
|
[18]
|
谢通, 沈琳. 2021年度胃癌治疗进展[J]. 肿瘤综合治疗电子杂志, 2022, 8(1): 56-60
|
[19]
|
Qi, C., Qin, Y., Liu, D., Gong, J., Ge, S., Zhang, M., et al. (2021) 1372O CLDN 18.2-Targeted CAR-T Cell Therapy in Patients with Cancers of the Digestive System. Annals of Oncology, 32, S1040.
https://doi.org/10.1016/j.annonc.2021.08.1481
|
[20]
|
Peng, Z., Liu, T., Wei, J., Wang, A., He, Y., Yang, L., et al. (2021) Efficacy and Safety of a Novel Anti-HER2 Therapeutic Antibody RC48 in Patients with HER2- Overexpressing, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer: A Single-Arm Phase II Study. Cancer Communications, 41, 1173-1182.
https://doi.org/10.1002/cac2.12214
|
[21]
|
Shitara, K., Bang, Y.J., Iwasa, S., Sugimoto, N., Ryu, M.H., Sakai, D., et al. (2020) Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. The New England Journal of Medicine, 382, 2419-2430.
https://doi.org/10.1056/NEJMoa2004413
|
[22]
|
Janjigian, Y.Y., Kawazoe, A., Yañez, P., Li, N., Lonardi, S., Kole-snik, O., et al. (2021) The KEYNOTE-811 Trial of Dual PD-1 and HER2 Blockade in HER2-Positive Gastric Cancer. Nature, 600, 727-730.
https://doi.org/10.1038/s41586-021-04161-3
|
[23]
|
Zhang, J., Dong, R. and Shen, L. (2020) Evaluation and Reflec-tion on Claudin 18.2 Targeting Therapy in Advanced Gastric Cancer. Chinese Journal of Cancer Research, 32, 263-270.
https://doi.org/10.21147/j.issn.1000-9604.2020.02.13
|
[24]
|
Sahin, U., Koslowski, M., Dhaene, K., Usener, D., Brandenburg, G., Seitz, G., et al. (2008) Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development. Clinical Cancer Research, 14, 7624-7634.
https://doi.org/10.1158/1078-0432.CCR-08-1547
|
[25]
|
Sahin, U., Türeci, Ö., Manikhas, G., Lordick, F., Rusyn, A., et al. (2021) FAST: A Randomised Phase II Study of Zolbetuximab (IMAB362) plus EOX versus EOX alone for First-Line Treatment of Advanced CLDN18.2-Positive Gastric and Gastro-Oesophageal Adenocarcinoma. Annals of Oncology, 32, 609-619.
https://doi.org/10.1016/j.annonc.2021.02.005
|